Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025)
Arcellx (ACLX) recorded quarterly Liabilities and Shareholders Equity of $604.0 million in Q4 2025, down 7.92% quarter-over-quarter from $655.9 million in Q3 2025, and down 15.09% on a YoY basis from $711.3 million in Q4 2024.
Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends
Arcellx's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $604.0 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 15.09% year-over-year to $604.0 million; the TTM figure through Dec 2025 stood at $2.5 billion (down 15.49% YoY), while the FY2025 annual figure was $604.0 million, down 15.09% from the prior year.
- Liabilities and Shareholders Equity was $604.0 million for Q4 2025 at Arcellx, down from $655.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $825.1 million in Q4 2023 to a low of $128.8 million in Q4 2021.
- Historically, Liabilities and Shareholders Equity has averaged $565.0 million across 5 years, with a median of $622.9 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 162.93% in 2023, then slipped 16.88% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $128.8 million in 2021, then soared by 143.68% to $313.8 million in 2022, then soared by 162.93% to $825.1 million in 2023, then fell by 13.79% to $711.3 million in 2024, then slipped by 15.09% to $604.0 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $604.0 million (Q4 2025), $655.9 million (Q3 2025), and $619.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 603.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 603.99 Mn |
| Sep 30, 2025 | 655.92 Mn |
| Jun 30, 2025 | 619.09 Mn |
| Mar 31, 2025 | 648.08 Mn |
| Dec 31, 2024 | 711.33 Mn |
| Sep 30, 2024 | 764.91 Mn |
| Jun 30, 2024 | 734.31 Mn |
| Mar 31, 2024 | 779.70 Mn |
| Dec 31, 2023 | 825.13 Mn |
| Sep 30, 2023 | 614.22 Mn |
| Jun 30, 2023 | 623.53 Mn |
| Mar 31, 2023 | 622.94 Mn |
| Dec 31, 2022 | 313.82 Mn |
| Sep 30, 2022 | 337.33 Mn |
| Jun 30, 2022 | 374.66 Mn |
| Mar 31, 2022 | 246.98 Mn |
| Dec 31, 2021 | 128.78 Mn |